Immunovant, Inc. (IMVT)
| Market Cap | 2.07B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -198.70M |
| Shares Out | 130.25M |
| EPS (ttm) | -1.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 204,207 |
| Open | 16.15 |
| Previous Close | 15.71 |
| Day's Range | 15.90 - 16.52 |
| 52-Week Range | 3.15 - 20.24 |
| Beta | 1.05 |
| Analysts | Buy |
| Price Target | 24.28 (+52.7%) |
| Earnings Date | Feb 3, 2023 |
About IMVT
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquar... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for IMVT stock is "Buy." The 12-month stock price forecast is $24.28, which is an increase of 52.70% from the latest price.
News
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022
NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today re...
4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023
Here are four drug companies, MRK, VRTX, IMCR and IMVT, that are up 40% or more in 2022 so far and still have room for growth in 2023.
Are Medical Stocks Lagging Immunovant (IMVT) This Year?
Here is how Immunovant, Inc. (IMVT) and McKesson (MCK) have performed compared to their sector so far this year.
Reasons to Add Immunovant (IMVT) Stock to Your Portfolio Now
Immunovant (IMVT) is progressing well with its lead pipeline candidate batoclimab being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.
Immunovant (IMVT) Rises More Than 150% in 3 Months: Here's How
Immunovant (IMVT) is making good progress with its lead pipeline candidate, batoclimab, which is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.
Immunovant's (IMVT) Q2 Earnings In Line, Batoclimab in Focus
Immunovant's (IMVT) earnings meet estimates in the fiscal second quarter ending Sep 30, 2022. IMVT deepens focus on developing its lead candidate batoclimab.
Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th
NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today an...
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022
NEW YORK, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today re...
Immunovant (IMVT) Set to Develop Lead Candidate Batoclimab
Immunovant (IMVT) expects its lead pipeline candidate, batoclimab, being developed for treating several types of autoimmune diseases, to capture good market share, owing to its differentiated profile.
Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock
NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today an...
Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn
NEW YORK, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today ...
Immunovant to Present at Roivant Investor Day on September 28th
NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today a...
Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th
NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today a...
UPDATE -- Immunovant Announces Two New Development Programs for Batoclimab
NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today ann...
Immunovant Announces Two New Development Programs for Batoclimab
NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today ann...
Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why
Immunovant's (IMVT) lead pipeline candidate, batoclimab, is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.
Immunovant, Inc. (IMVT) Upgraded to Buy: Here's Why
Immunovant, Inc. (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See an 114% Upside in Immunovant, Inc. (IMVT): Can the Stock Really Move This High?
The consensus price target hints at an 114.4% upside potential for Immunovant, Inc. (IMVT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earning...
Immunovant to Host Investor Webcast to Announce Two New Indications for Batoclimab on September 7, 2022
NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, will host ...
GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance
GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.
Immunovant (IMVT) Focus on Developing Autoimmune Disease Drug
Immunovant (IMVT) remains focused on developing its lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. The lack of other pipeline candidates remains a concern.
Wall Street Analysts Think Immunovant, Inc. (IMVT) Could Surge 142%: Read This Before Placing a Bet
The mean of analysts' price targets for Immunovant, Inc. (IMVT) points to a 142.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amon...
Immunovant (IMVT) Loss Narrows in Q1, Focus on Batoclimab
Immunovant's (IMVT) earnings beat estimates in the fiscal first quarter ended on Jun 30, 2022. The company is evaluating batoclimab in a pivotal study for treating myasthenia gravis.
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended June 30, 2022
NEW YORK, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today repo...
Why Is Immunovant, Inc. (IMVT) Up 13.9% Since Last Earnings Report?
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock?